133 related articles for article (PubMed ID: 33837974)
1. The Impact of Telmisartan on Cardiometabolic Risk Factors in Hypertensive Male Siblings of Women With Polycystic Ovary Syndrome.
Krysiak R; Basiak M; Szkróbka W; Okopień B
J Clin Pharmacol; 2021 Sep; 61(9):1165-1173. PubMed ID: 33837974
[TBL] [Abstract][Full Text] [Related]
2. The impact of atorvastatin on cardiometabolic risk factors in brothers of women with polycystic ovary syndrome.
Krysiak R; Szkróbka W; Okopień B
Pharmacol Rep; 2021 Feb; 73(1):261-268. PubMed ID: 32696349
[TBL] [Abstract][Full Text] [Related]
3. Impact of Lisinopril on Cardiometabolic Risk Factors in Sisters of Women With Polycystic Ovary Syndrome.
Krysiak R; Kowalcze K; Okopień B
J Clin Pharmacol; 2023 Sep; 63(9):1045-1052. PubMed ID: 37173821
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Atorvastatin on Cardiometabolic Risk Factors in Sisters of Women with Polycystic Ovary Syndrome.
Krysiak R; Kowalcze K; Okopień B
Pharmacology; 2023; 108(5):451-459. PubMed ID: 37536301
[TBL] [Abstract][Full Text] [Related]
5. The effect of short-term perindopril and telmisartan treatment on circulating levels of anti-inflammatory cytokines in hypertensive patients.
Gilowski W; Krysiak R; Marek B; Okopień B
Endokrynol Pol; 2018; 69(6):667-674. PubMed ID: 30259507
[TBL] [Abstract][Full Text] [Related]
6. Impact of Lisinopril on Cardiometabolic Risk Factors in Men With Hypertension and Early-onset Androgenetic Alopecia: A Pilot Study.
Krysiak R; Basiak M; Okopień B
J Cardiovasc Pharmacol; 2021 Nov; 78(5):e738-e742. PubMed ID: 34321400
[TBL] [Abstract][Full Text] [Related]
7. Decreased androgen levels and improved menstrual pattern after angiotensin II receptor antagonist telmisartan treatment in four hypertensive patients with polycystic ovary syndrome: case series.
Jensterle M; Janez A; Vrtovec B; Meden-Vrtovec H; Pfeifer M; Prezelj J; Kocjan T
Croat Med J; 2007 Dec; 48(6):864-70. PubMed ID: 18074422
[TBL] [Abstract][Full Text] [Related]
8. High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS).
Ganie MA; Hassan S; Nisar S; Shamas N; Rashid A; Ahmed I; Douhat S; Mudassar S; Jan VM; Rashid F
Gynecol Endocrinol; 2014 Nov; 30(11):781-4. PubMed ID: 25137507
[TBL] [Abstract][Full Text] [Related]
9. Impaired Cardiometabolic Effects of Bromocriptine in Men With Early-Onset Androgenic Alopecia.
Krysiak R; Basiak M; Szkróbka W; Okopień B
J Clin Pharmacol; 2023 Mar; 63(3):345-351. PubMed ID: 36222207
[TBL] [Abstract][Full Text] [Related]
10. Glucose intolerance, insulin resistance and cardiovascular risk factors in first degree relatives of women with polycystic ovary syndrome.
Yilmaz M; Bukan N; Ersoy R; Karakoç A; Yetkin I; Ayvaz G; Cakir N; Arslan M
Hum Reprod; 2005 Sep; 20(9):2414-20. PubMed ID: 15890734
[TBL] [Abstract][Full Text] [Related]
11. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome.
Yildiz BO; Yarali H; Oguz H; Bayraktar M
J Clin Endocrinol Metab; 2003 May; 88(5):2031-6. PubMed ID: 12727950
[TBL] [Abstract][Full Text] [Related]
12. ACC/AHA 2017 definition of high blood pressure: implications for women with polycystic ovary syndrome.
Marchesan LB; Spritzer PM
Fertil Steril; 2019 Mar; 111(3):579-587.e1. PubMed ID: 30827526
[TBL] [Abstract][Full Text] [Related]
13. Cardiometabolic Risk Factors in Rosuvastatin-Treated Men with Mixed Dyslipidemia and Early-Onset Androgenic Alopecia.
Krysiak R; Basiak M; Okopień B
Molecules; 2021 May; 26(10):. PubMed ID: 34064815
[TBL] [Abstract][Full Text] [Related]
14. Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients.
Vecchiet J; Ucciferri C; Falasca K; Mancino P; Di Iorio A; De Caterina R
Antivir Ther; 2011; 16(5):639-45. PubMed ID: 21817185
[TBL] [Abstract][Full Text] [Related]
15. Disparities in cardio metabolic risk between Black and White women with polycystic ovary syndrome: a systematic review and meta-analysis.
Kazemi M; Kim JY; Parry SA; Azziz R; Lujan ME
Am J Obstet Gynecol; 2021 May; 224(5):428-444.e8. PubMed ID: 33316275
[TBL] [Abstract][Full Text] [Related]
16. Androgen levels in women with various forms of ovarian dysfunction: associations with cardiometabolic features.
Daan NM; Jaspers L; Koster MP; Broekmans FJ; de Rijke YB; Franco OH; Laven JS; Kavousi M; Fauser BC
Hum Reprod; 2015 Oct; 30(10):2376-86. PubMed ID: 26269538
[TBL] [Abstract][Full Text] [Related]
17. Bioavailable and free 25-hydroxyvitamin D and vitamin D binding protein in polycystic ovary syndrome: Relationships with obesity and insulin resistance.
Naderpoor N; Shorakae S; Abell SK; Mousa A; Joham AE; Moran LJ; Stepto NK; Spritzer PM; Teede HJ; de Courten B
J Steroid Biochem Mol Biol; 2018 Mar; 177():209-215. PubMed ID: 28734987
[TBL] [Abstract][Full Text] [Related]
18. [Relationship between the triglyceride/high-density lipoprotein-cholesterol ratio, insulin resistance index and cardiometabolic risk factors in women with polycystic ovary syndrome].
Roa Barrios M; Arata-Bellabarba G; Valeri L; Velázquez-Maldonado E
Endocrinol Nutr; 2009 Feb; 56(2):59-65. PubMed ID: 19627713
[TBL] [Abstract][Full Text] [Related]
19. Cardiometabolic Risk Factors in Men with Elevated Macroprolactin Content: A Pilot Study.
Krysiak R; Szkróbka W; Okopień B
Exp Clin Endocrinol Diabetes; 2021 Jan; 129(1):7-13. PubMed ID: 31185509
[TBL] [Abstract][Full Text] [Related]
20. Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives.
Sanchez RA; Masnatta LD; Pesiney C; Fischer P; Ramirez AJ
J Hypertens; 2008 Dec; 26(12):2393-8. PubMed ID: 19008718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
